Furthermore, evaluation of local failure rate and localization of local recurrences will demonstrate whether the postulated improved sensitivity and tumor coverage by inclusion of PSMA-PET to ITM delineation is of clinical relevance. The gene discussed is FOLH1; the disease is neoplasm.